The Integrin Beta 3 pipeline drugs market research report outlays comprehensive information on the Integrin Beta 3 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Integrin Beta 3 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Cardiovascular, Ophthalmology, and Infectious Disease which include the indications Solid Tumor, Non-Small Cell Lung Cancer, Thrombosis, Myocardial Infarction, Diabetic Macular Edema, Wet (Neovascular / Exudative) Macular Degeneration, Sepsis, and Escherichia coli Sepsis. It also reviews key players involved in Integrin Beta 3 targeted therapeutics development with respective active and dormant or discontinued products.
The Integrin Beta 3 pipeline targets constitutes close to 31 molecules. Out of which, approximately 21 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/ CTA Filed, and Preclinical stages are 1, 5, 6, 1, and 8 respectively. Similarly, the universities portfolio in Phase I, Preclinical, and Discovery comprises 1, 8, and 1 molecule.
Integrin Beta 3 overview
Integrin beta-3 (β3) or CD61 is a protein that in humans is encoded by the ITGB3 gene. Integrin beta 3 is found along with the alpha IIb chain in platelets. It is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Activation of integrin alpha-IIb/beta-3 leads to platelet interaction through binding of soluble fibrinogen. This leads to rapid platelet aggregation which physically plugs ruptured endothelial surface.
For a complete picture of Integrin Beta 3’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
